Moreover, lipiodol can mask assessment of residual vascularity on CT imaging following locoregional therapy and this is a major disadvantage. In a cohort of 62 patients with HCC there were 141 ...

在 HCC 中，多条信号通路失调，导致癌细胞不受控制地增殖、转移和复发。除了 HCC 中频繁改变且作为治疗靶点的受体酪氨酸激酶（RTK）通路外，参与细胞分化、端粒调节、表观遗传修饰和应激反应的通路也具有治疗潜力。研究关键信号通路及其抑制剂对于实现 HCC 治疗的进展至关重要。

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Hepatobiliary cancers, which include biliary tract cancer (BTC) and hepatocellular carcinoma (HCC), are among the most lethal ...

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

Tyrosine kinase inhibitor (TKI) Nexavar has been the mainstay of first-line HCC therapy for years, but prognosis for patients continues to be poor and there’s a big unmet need for drugs that can ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy ...

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Sorafenib (BAY43–9006) is currently the only approved systemic treatment for HCC. It has been approved for the therapy of asymptomatic HCC patients with well-preserved liver function who are not ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.